Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
3hon MSN
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...
Celebrities' use of weight loss drugs like Ozempic and Wegovy has surged, including Sharon Osbourne and Elon Musk. However, users report severe side effects such as erectile dysfunction and reduced ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback